nct_id
stringlengths 11
11
| nlm_download_date_description
float64 | study_first_submitted_date
stringlengths 10
10
| results_first_submitted_date
stringlengths 10
10
⌀ | disposition_first_submitted_date
stringclasses 493
values | last_update_submitted_date
stringlengths 10
10
| study_first_submitted_qc_date
stringlengths 10
10
| study_first_posted_date
stringlengths 10
10
| study_first_posted_date_type
stringclasses 2
values | results_first_submitted_qc_date
stringlengths 10
10
⌀ | results_first_posted_date
stringlengths 10
10
⌀ | results_first_posted_date_type
stringclasses 2
values | disposition_first_submitted_qc_date
stringclasses 321
values | disposition_first_posted_date
stringclasses 478
values | disposition_first_posted_date_type
stringclasses 2
values | last_update_submitted_qc_date
stringlengths 10
10
| last_update_posted_date
stringlengths 10
10
| last_update_posted_date_type
stringclasses 2
values | start_month_year
stringlengths 7
10
⌀ | start_date_type
stringclasses 2
values | start_date
stringlengths 10
10
⌀ | verification_month_year
stringclasses 151
values | verification_date
stringclasses 151
values | completion_month_year
stringlengths 7
10
| completion_date_type
stringclasses 2
values | completion_date
stringlengths 10
10
| primary_completion_month_year
stringlengths 7
10
| primary_completion_date_type
stringclasses 2
values | primary_completion_date
stringlengths 10
10
| target_duration
float64 | study_type
stringclasses 1
value | acronym
stringlengths 2
14
⌀ | baseline_population
stringlengths 2
501
⌀ | brief_title
stringlengths 18
300
| official_title
stringlengths 28
563
⌀ | overall_status
stringclasses 4
values | last_known_status
float64 | phase
stringclasses 7
values | enrollment
float64 0
477k
| enrollment_type
stringclasses 2
values | source
stringlengths 3
107
| limitations_and_caveats
stringlengths 10
503
⌀ | number_of_arms
float64 1
27
⌀ | number_of_groups
float64 | why_stopped
stringlengths 3
252
⌀ | has_expanded_access
stringclasses 2
values | expanded_access_type_individual
float64 | expanded_access_type_intermediate
float64 | expanded_access_type_treatment
float64 | has_dmc
stringclasses 2
values | is_fda_regulated_drug
stringclasses 2
values | is_fda_regulated_device
stringclasses 2
values | is_unapproved_device
stringclasses 1
value | is_ppsd
float64 | is_us_export
stringclasses 2
values | biospec_retention
float64 | biospec_description
float64 | ipd_time_frame
stringclasses 442
values | ipd_access_criteria
stringclasses 465
values | ipd_url
stringclasses 124
values | plan_to_share_ipd
stringclasses 3
values | plan_to_share_ipd_description
stringlengths 3
998
⌀ | created_at
stringclasses 526
values | updated_at
stringclasses 526
values | source_class
stringclasses 8
values | delayed_posting
float64 | expanded_access_nctid
stringclasses 80
values | expanded_access_status_for_nctid
stringclasses 4
values | fdaaa801_violation
float64 | baseline_type_units_analyzed
stringclasses 11
values | patient_registry
float64 | completion_year
int64 2.02k
2.02k
| labels
float64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03867370 | null | 2019-03-01 | null | null | 2023-11-24 | 2019-03-05 | 2019-03-08 | ACTUAL | null | null | null | null | null | null | 2023-11-24 | 2023-11-29 | ACTUAL | 2019-04-26 | ACTUAL | 2019-04-26 | 2023-11 | 2023-11-30 | 2023-08-08 | ACTUAL | 2023-08-08 | 2023-08-08 | ACTUAL | 2023-08-08 | null | INTERVENTIONAL | null | null | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | A Phase Ib/II, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of Neoadjuvant Toripalimab Injection (JS001) or Toripalimab in Combination With Lenvatinib for Patients With Resectable Hepatocellular Carcinoma (HCC) | TERMINATED | null | PHASE1/PHASE2 | 40 | ACTUAL | Shanghai Junshi Bioscience Co., Ltd. | null | 3 | null | Enrollment is over, the study was completed | f | null | null | null | null | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,023 | 0 |
NCT04129151 | null | 2019-10-14 | 2024-04-24 | null | 2024-07-31 | 2019-10-15 | 2019-10-16 | ACTUAL | 2024-06-19 | 2024-07-17 | ACTUAL | null | null | null | 2024-07-31 | 2024-08-01 | ACTUAL | 2019-12-05 | ACTUAL | 2019-12-05 | 2024-07 | 2024-07-31 | 2022-12-15 | ACTUAL | 2022-12-15 | 2022-12-15 | ACTUAL | 2022-12-15 | null | INTERVENTIONAL | null | null | Palbociclib + Ganitumab In Ewing Sarcoma | Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing Sarcoma | TERMINATED | null | PHASE2 | 10 | ACTUAL | Dana-Farber Cancer Institute | The study terminated before full accrual. | 1 | null | The study closed early due to discontinuation of ganitumab supply. | f | null | null | null | t | t | f | null | null | null | null | null | Data can be shared no earlier than 1 year following the date of publication | Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu | null | YES | The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: contact Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,022 | 0 |
NCT03629275 | null | 2018-07-23 | null | null | 2021-08-12 | 2018-08-10 | 2018-08-14 | ACTUAL | null | null | null | null | null | null | 2021-08-12 | 2021-08-13 | ACTUAL | 2018-08-31 | ACTUAL | 2018-08-31 | 2021-08 | 2021-08-31 | 2021-03-02 | ACTUAL | 2021-03-02 | 2020-09-09 | ACTUAL | 2020-09-09 | null | INTERVENTIONAL | PISCES III | null | Investigation of Neural Stem Cells in Ischemic Stroke | A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke | TERMINATED | null | PHASE2 | 15 | ACTUAL | ReNeuron Limited | null | 2 | null | Strategic decision to progress stroke disability programme through regional partnerships | f | null | null | null | t | t | t | t | null | null | null | null | null | null | null | null | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03364270 | null | 2017-12-01 | 2021-08-11 | null | 2022-07-19 | 2017-12-01 | 2017-12-06 | ACTUAL | 2022-07-18 | 2022-07-20 | ACTUAL | null | null | null | 2022-07-19 | 2022-08-09 | ACTUAL | 2018-10-10 | ACTUAL | 2018-10-10 | 2022-07 | 2022-07-31 | 2020-05-31 | ACTUAL | 2020-05-31 | 2020-02-28 | ACTUAL | 2020-02-28 | null | INTERVENTIONAL | K5-C200 | null | TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study | An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis | COMPLETED | null | PHASE2 | 6 | ACTUAL | Cedars-Sinai Medical Center | Small sample size Differences in the time between imaging and symptoms of stroke or transient ischemic attack | 1 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT05065411 | null | 2021-09-21 | null | null | 2024-02-23 | 2021-09-22 | 2021-10-04 | ACTUAL | null | null | null | null | null | null | 2024-02-23 | 2024-02-26 | ACTUAL | 2022-04-11 | ACTUAL | 2022-04-11 | 2024-02 | 2024-02-29 | 2024-01-09 | ACTUAL | 2024-01-09 | 2023-10-19 | ACTUAL | 2023-10-19 | null | INTERVENTIONAL | VERU-024 | null | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer | P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib | TERMINATED | null | PHASE3 | 5 | ACTUAL | Veru Inc. | null | 2 | null | Business decision | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | UNDECIDED | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03526588 | null | 2018-04-27 | null | null | 2024-07-09 | 2018-05-15 | 2018-05-16 | ACTUAL | null | null | null | null | null | null | 2024-07-09 | 2024-07-11 | ACTUAL | 2018-08-01 | ACTUAL | 2018-08-01 | 2024-07 | 2024-07-31 | 2024-07-01 | ACTUAL | 2024-07-01 | 2022-07-01 | ACTUAL | 2022-07-01 | null | INTERVENTIONAL | null | null | Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH) | Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH) | TERMINATED | null | PHASE1 | 3 | ACTUAL | The University of Texas Health Science Center, Houston | null | 1 | null | Competing randomized trial of an experimental therapy limited initial enrollment. The trial was completed, published, and the experimental therapy became broadly desired. Given this, the investigators felt it best to terminate this competing study. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,024 | 0 |
NCT03615040 | null | 2018-05-04 | 2022-01-06 | null | 2022-05-24 | 2018-07-30 | 2018-08-03 | ACTUAL | 2022-05-23 | 2022-05-24 | ACTUAL | null | null | null | 2022-05-24 | 2022-06-21 | ACTUAL | 2018-10-11 | ACTUAL | 2018-10-11 | 2020-06 | 2020-06-30 | 2020-12-31 | ACTUAL | 2020-12-31 | 2020-05-29 | ACTUAL | 2020-05-29 | null | INTERVENTIONAL | COPD-ST2OP | null | Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) | A Randomised Placebo-controlled Trial of Anti-ST2 in COPD (COPD-ST2OP) | COMPLETED | null | PHASE2 | 81 | ACTUAL | University of Leicester | * Small sample size (n=81) at a single site, therefore not powered to detect a reduction in exacerbation frequency that was observed.~* Participants were required to have had a minimum of 2 exacerbations in the previous 12 months, so the findings are not representative for a wider clinical population.~* In response to COVID-19, collection of secondary/exploratory outcomes were reduced, with spirometry and sputum induction discontinued. | 2 | null | null | null | null | null | null | t | t | f | null | null | t | null | null | null | null | null | NO | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,020 | 1 |
NCT03630770 | null | 2018-07-25 | 2021-11-02 | null | 2022-03-10 | 2018-08-09 | 2018-08-15 | ACTUAL | 2022-03-10 | 2022-06-14 | ACTUAL | null | null | null | 2022-03-10 | 2022-06-14 | ACTUAL | 2014-06-05 | ACTUAL | 2014-06-05 | 2022-03 | 2022-03-31 | 2021-11-02 | ACTUAL | 2021-11-02 | 2017-11-29 | ACTUAL | 2017-11-29 | null | INTERVENTIONAL | null | null | Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida | Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida | COMPLETED | null | PHASE1 | 12 | ACTUAL | Women and Infants Hospital of Rhode Island | null | 2 | null | null | f | null | null | null | f | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,021 | 1 |
NCT05621525 | null | 2022-11-10 | null | null | 2024-06-24 | 2022-11-10 | 2022-11-18 | ACTUAL | null | null | null | null | null | null | 2024-06-24 | 2024-06-25 | ACTUAL | 2022-10-18 | ACTUAL | 2022-10-18 | 2024-06 | 2024-06-30 | 2024-03-29 | ACTUAL | 2024-03-29 | 2024-03-29 | ACTUAL | 2024-03-29 | null | INTERVENTIONAL | null | null | Phase I Study of the BBP-398 in Patients With Advance Solid Tumors | A Phase I, Open Label, Dose Escalation and Expansion, Two- Part Study of SHP-2 Inhibitor BBP-398 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-cancer Activity in Chinese Subjects With Advanced Solid Tumors | TERMINATED | null | PHASE1 | 7 | ACTUAL | LianBio LLC | null | 1 | null | Business reason | f | null | null | null | f | f | f | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | INDUSTRY | null | null | null | null | null | null | 2,024 | 0 |
NCT03642132 | null | 2018-07-13 | 2022-12-06 | null | 2023-03-10 | 2018-08-20 | 2018-08-22 | ACTUAL | 2023-03-10 | 2023-04-06 | ACTUAL | null | null | null | 2023-03-10 | 2023-04-06 | ACTUAL | 2018-07-19 | ACTUAL | 2018-07-19 | 2023-03 | 2023-03-31 | 2021-12-22 | ACTUAL | 2021-12-22 | 2021-12-22 | ACTUAL | 2021-12-22 | null | INTERVENTIONAL | null | The baseline analysis population included all randomized participants who received at least 1 dose of study drug (avelumab, talazoparib, bevacizumab, carboplatin, paclitaxel). | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100) | TERMINATED | null | PHASE3 | 79 | ACTUAL | Pfizer | As of 19 March 2019, the sponsor decided to stop enrollment/randomization in the study. A total of 104 participants were screened and 79 participants completed screening and randomized in the study before study discontinuation. As only 11% projected enrollment was met at the time of enrollment stop, the original study endpoints are no longer applicable and/or feasible; only the Safety, PK and Immunogenicity Analysis were done and these data are included in this report. | 3 | null | Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on 21Dec2018, and approvals of PARP inhibitors in front-line maintenance setting, Pfizer decided stopping enrollment in the B9991030 study on 19Mar2019. | f | null | null | null | t | t | f | null | null | null | null | null | null | null | https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests | YES | Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests. | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | INDUSTRY | null | null | null | null | null | null | 2,021 | 0 |
NCT03631641 | null | 2018-08-13 | 2022-11-09 | null | 2024-06-27 | 2018-08-13 | 2018-08-15 | ACTUAL | 2024-06-27 | 2024-07-01 | ACTUAL | null | null | null | 2024-06-27 | 2024-07-01 | ACTUAL | 2018-10-04 | ACTUAL | 2018-10-04 | 2024-06 | 2024-06-30 | 2021-01-25 | ACTUAL | 2021-01-25 | 2021-01-25 | ACTUAL | 2021-01-25 | null | INTERVENTIONAL | null | null | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial Colectomy | TERMINATED | null | PHASE2 | 3 | ACTUAL | Ohio State University Comprehensive Cancer Center | Trial stopped early due to withdrawal of pharmaceutical sponsor support | 1 | null | Sponsor decision | null | null | null | null | t | t | f | null | null | null | null | null | null | null | null | NO | null | 2024-10-17 02:29:59.152132 | 2024-10-17 02:29:59.152132 | OTHER | null | null | null | null | null | null | 2,021 | 0 |
NCT02543749 | null | 2015-08-25 | null | null | 2023-02-07 | 2015-09-04 | 2015-09-07 | ESTIMATED | null | null | null | null | null | null | 2023-02-07 | 2023-02-09 | ACTUAL | 2014-07 | null | 2014-07-31 | 2023-02 | 2023-02-28 | 2022-07 | ACTUAL | 2022-07-31 | 2022-07 | ACTUAL | 2022-07-31 | null | INTERVENTIONAL | null | null | DC Vaccination in CML | Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia | TERMINATED | null | PHASE1/PHASE2 | 1 | ACTUAL | Charite University, Berlin, Germany | null | 1 | null | null | f | null | null | null | f | null | null | null | null | null | null | null | null | null | null | null | null | 2024-10-15 06:29:28.751562 | 2024-10-15 06:29:28.751562 | OTHER | null | null | null | null | null | null | 2,022 | 0 |